Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Tables)

v2.4.0.8
Commitments and Contingencies (Tables)
 9 Months Ended
Sep. 30, 2013
Abbott Biotherapeutics Corp [Member]
  
Milestone Payments Milestone Method [Line Items]  
Summary of milestone payment
 
Milestones
 
Payments
 
 
 
 
 
(1) when Company initiates a Phase I Clinical Trial of a licensed product
 
$
750,000
 
(2) when Company initiates a Phase II Clinical Trial of a licensed product
 
 
750,000
 
(3) when Company initiates a Phase III Clinical Trial of a licensed product
 
 
1,500,000
 
(4) Biological License Application filing with U.S. FDA
 
 
1,750,000
 
(5) First commercial sale
 
 
1,500,000
 
(6) after the first $10,000,000 in net sales
 
 
1,500,000
 
MSKCC [Member]
  
Milestone Payments Milestone Method [Line Items]  
Summary of milestone payment
 
 
 
Milestones
 
Payments
 
 
 
 
 
 
 
 
 
1) filing of an New Drug Application (“NDA”) or regulatory approval for each licensed product
 
$
750,000
 
(2) upon the receipt of regulatory approval from the U.S. FDA for each licensed product
 
 
1,750,000